Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI101 (Cudarolimab) Monotherapy or with Sintilimab in Advanced Solid Tumors
NCT03758001Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Feb 2019
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of cudarolimab in solid tumor (advanced stage) (2 arms), sponsored by Innovent Biologics. Primary endpoint: Incicende of Adverse Events (AEs) at 2 years. Started Feb 2019; status: completed.
02
Drugs
cudarolimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03758001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03758001.